Objective To investigate the effects of ketorolac tromethamine and parecoxib sodium on postoperative blood loss of patients after transforaminal lumbar interbody fusion (TLIF).
Methods Fifty-nine patients who underwent TLIF surgery for single-level lumbar spinal stenosis were selected as subjects, and randomly divided into ketorolac tromethamine group (n=31) and parecoxib sodium group (n=28). The ketorolac tromethamine group was given 30 mg of ketorolac tromethamine intravenously, twice a day, for a total of 3 days after surgery, while the parecoxib sodium group was given 40 mg of parecoxib sodium intravenously, twice a day, for a total of 3 days. The general information, operation time, intraoperative blood loss, postoperative drainage volume and dominant blood loss of two groups were counted. The indexes of blood cell analysis, blood coagulation function, liver and kidney function before and after operation were detected, and the total blood loss and latent blood loss were calculated.
Results The total blood loss, dominant blood loss and postoperative drainage volume in the parecoxib sodium group were significantly less than those in the ketorolac tromethamine group (P < 0.05). Postoperative prothrombin time and activated partial thromboplastin time in the parecoxib sodium group were significantly longer than those in the ketorolac tromethamine group (P < 0.05).
Conclusion Compared with ketorolac tromethamine, the use of parecoxib sodium after TLIF can reduce postoperative total blood loss, dominant blood loss and drainage volume, but it has little effect on latent blood loss. In addition, parecoxib sodium may have less effect on blood coagulation function.
DownLoad: